Want to see HK:2179 full AI Analyst Report?
2179 Stock Chart & Stats
HK$4.18
-HK$0.53(-6.02%)
At close: 4:00 PM EST
HK$4.18
-HK$0.53(-6.02%)
Day’s Range― - ―
52-Week RangeHK$3.40 - HK$8.80
Previous CloseN/A
Volume13.00K
Average Volume (3M)18.23K
Market Cap
HK$3.14B
Enterprise ValueHK$2.80K
Total Cash (Recent Filing)HK$351.99M
Total Debt (Recent Filing)HK$638.75M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding458,092,160
10 Day Avg. Volume1,300
30 Day Avg. Volume18,233
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.70
Price to Sales (P/S)153.96
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Vaccine And Biologics FocusA core business centered on vaccines and innovative biologics aligns with durable structural demand for preventive medicines and public-health driven procurement. Long product development cycles and persistent global need can create recurring revenue streams and long product lifecycles once commercialized.
Improving LeverageMaterial reduction in debt-to-equity meaningfully lowers financial risk and interest burden, improving flexibility to fund R&D or scale manufacturing. This balance-sheet improvement enhances resilience over months and reduces refinancing pressure versus prior periods of higher leverage.
Free Cash Flow Trend ImprovementAn improving free cash flow trajectory signals early progress on cash conversion and operational efficiency. While still negative, sustained improvement over consecutive periods would reduce reliance on external funding and indicates management actions that could support runway extension over the next several months.
Bears Say
Volatile, Shrinking RevenueA sharp ~57% revenue decline in 2025 highlights weak commercialization traction and low revenue visibility. Persistent revenue volatility undermines unit economics and scale benefits, complicates planning for manufacturing capacity and R&D prioritization, and raises execution risk over the medium term.
Persistent Cash BurnConsistent negative operating and free cash flow mandates continuous external funding to sustain operations. Ongoing cash burn erodes the asset base, increases dilution or refinancing risk, and constrains strategic options such as late-stage trials or commercial scale-up absent reliable funding sources.
Negative Gross Profit And Deep LossesNegative gross profit indicates product mix, pricing or cost structure issues that hit fundamental unit economics. Deep operating losses and negative margins cannot be fixed by short-term cuts alone; they require structural changes to pricing, cost base, or product mix to achieve sustainable profitability.
Jiangsu Recbio Technology Co., Ltd. Class H News
2179 FAQ
What was Jiangsu Recbio Technology Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Recbio Technology Co., Ltd. Class H lowest stock price was HK$3.40 and its highest was HK$8.80 in the past 12 months.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s market cap?
Jiangsu Recbio Technology Co., Ltd. Class H’s market cap is HK$3.14B.
When is Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date?
Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2026 which is in 34 days.
How were Jiangsu Recbio Technology Co., Ltd. Class H’s earnings last quarter?
Jiangsu Recbio Technology Co., Ltd. Class H released its earnings results on Mar 24, 2026. The company reported -HK$0.477 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Jiangsu Recbio Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangsu Recbio Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Jiangsu Recbio Technology Co., Ltd. Class H pay dividends?
Jiangsu Recbio Technology Co., Ltd. Class H does not currently pay dividends.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate?
Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangsu Recbio Technology Co., Ltd. Class H have?
Jiangsu Recbio Technology Co., Ltd. Class H has 458,092,160 shares outstanding.
What happened to Jiangsu Recbio Technology Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Recbio Technology Co., Ltd. Class H reported an EPS of -HK$0.477 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.435%.
Which hedge fund is a major shareholder of Jiangsu Recbio Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2179
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangsu Recbio Technology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.26%
12-Months-Change
Fundamentals
Return on Equity
-137.11%
Trailing 12-Months
Asset Growth
-4.96%
Trailing 12-Months
Company Description
Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Technical Analysis
Genor Biopharma Holdings Limited
―
TOT BIOPHARM International Co. Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Clover Biopharmaceuticals Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―